SCHEMBL6643538

SCHEMBL6643538

Oc1ccc(Nc2ncc(Br)c(Nc3ccccc3)n2)c(F)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 7/20 0.63
▸ SYK P43405 4/20 0.62
▸ GSK3B P49841 2/20 0.55
▸ MAPK8 P45983 4/20 0.54
▸ AURKA O14965 6/20 0.52
▸ CDK1 P06493 2/20 0.52
▸ CDK2 P24941 2/20 0.52
▸ KDR P35968 2/20 0.52
▸ AURKB Q96GD4 2/20 0.52
▸ PLK4 O00444 1/20 0.52
▸ PDPK1 O15530 1/20 0.52
▸ JAK2 O60674 1/20 0.52
▸ PRKD3 O94806 1/20 0.52
▸ MAP4K4 O95819 1/20 0.52
▸ NTRK1 P04629 1/20 0.52
▸ INSR P06213 1/20 0.52
▸ LCK P06239 1/20 0.52
▸ FYN P06241 1/20 0.52
▸ FES P07332 1/20 0.52
▸ CSF1R P07333 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3270075 0.82 IGF1R (0.82) IGF1RSYKGSK3BMAPK8AURKA
SCHEMBL3275303 0.81 SYK (0.92) IGF1RSYKGSK3BMAPK8AURKA
SCHEMBL4459525 0.79 IGF1R (1.00) IGF1RSYKGSK3BMAPK8AURKA
SCHEMBL655851 0.78 AURKA (0.61) IGF1RSYKGSK3BMAPK8AURKA
SCHEMBL6829175 0.77 SYK (0.83) IGF1RSYKGSK3BMAPK8AURKA
SCHEMBL656905 0.77 SYK (1.00) IGF1RSYKGSK3BMAPK8CDK1
SCHEMBL6642447 0.76 IGF1R (0.50) IGF1RSYKGSK3BMAPK8AURKA
SCHEMBL7169368 0.76 CYP3A4 (0.52) —
SCHEMBL6826392 0.76 AURKA (0.67) IGF1RSYKGSK3BAURKACDK1
SCHEMBL5261726 0.72 IGF1R (0.85) IGF1RSYKGSK3BMAPK8AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140860-B1 PYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2004-09-22 — — EP disclosed
US-6593326-B1 Useful as anti-cancer agents; and processes for their manufacture and pharmaceutical compositions containing them are described. Apoptotic effect in a warm-blooded animal such as man. ASTRAZENECA AB (SE) 2003-07-15 — — US disclosed
EP-1140860-A1 PYRIMIDINE COMPOUNDS AstraZeneca AB (SE) 2001-10-10 — — EP disclosed
WO-2000039101-A1 PYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2000-07-06 — — WO disclosed
Send feedback